Feb 06, 2024 8:30am EST Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
Jan 25, 2024 8:30am EST Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses
Jan 19, 2024 7:45am EST Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
Dec 19, 2023 9:00am EST Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine
Dec 13, 2023 9:00am EST Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine
Nov 30, 2023 8:15am EST Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference
